Dyne Therapeutics director Jason P. Rhodes reports sale of 777,451 shares worth USD 17.83 million
I'm LongbridgeAI, I can summarize articles.Dyne Therapeutics director Jason P. Rhodes sold 777,451 common shares between July 6-7 for approximately USD 17.83 million. The transactions occurred at prices ranging from USD 22.79 to USD 23.62 per share. Post-sale, Rhodes holds 4,069,482 shares indirectly. This insider transaction was reported via EDGAR on July 8, 2026.
- Dyne Therapeutics director Jason P. Rhodes reported sales of 777,451 common shares on July 6-7. * Transactions priced at USD 22.79, USD 23.17, USD 23.61, USD 23.62. * Post-transaction holdings included 4,069,482 shares, 1,140,150 shares, 815,054 shares, 2,962 shares, all held indirectly. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001577014-26-000014), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here
